Radiation and hormone therapy before surgery for prostate cancer that has spread to a few spots
Part of Cancer, Hormones & metabolism, Kidney & urinary clinical trials.
This trial tests a new approach using radiation therapy (radiotherapy) combined with hormone therapy before the standard surgery to remove the prostate. It aims to see if this combination can better control prostate cancer that has spread to a few spots (oligometastatic) and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that is a type called adenocarcinoma (confirmed by biopsy).
- A PSMA PET/CT scan shows the cancer has spread to less than 4 spots in your bones or lymph nodes below your kidneys.
- You have not had any previous treatment for prostate cancer (such as surgery, radiation, hormone therapy, or chemotherapy).
- If you are taking blood thinners, you can stop them at least 1 week before the trial starts.
- You are in good general health (able to do daily activities, no serious infections or other cancers).
- You are willing to have robotic surgery to remove the prostate (RALP) as part of the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether radiation therapy can help treat prostate cancer that has spread to only a few places in the body (oligometastatic). It aims to see if targeting both the prostate and the small number of metastases can improve outcomes.
This trial tests whether giving intense hormone therapy along with either radiation or surgery can help men with prostate cancer that has spread to a limited number of spots (10 or fewer) but not to organs like the liver or lungs. The goal is to treat both the main tumor and the visible metastatic spots more aggressively.
This trial tests a shorter course of hormone therapy plus targeted radiation for prostate cancer that has spread to a few spots (oligometastatic). The goal is to see if less hormone therapy can still control the cancer effectively.
This trial tests whether giving precise radiation to a few spots of cancer growth can help control prostate cancer that has stopped responding to hormone therapy. It is for people with up to 3 growing or new spots of cancer on a special scan.
This study tests whether adding a type of high-precision radiation (MDRT) to standard hormone therapy works better for men with prostate cancer that has spread to just a few places. It is for patients who are newly diagnosed and on long-term hormone therapy.
This trial studies whether adding focused radiation (SBRT) to hormone therapy can control prostate cancer that has spread to only a few places. It aims to help people with early “oligometastatic” prostate cancer by improving disease control while limiting treatment side effects.
Hear when a new Oligometastatic Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.